Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab with Tislelizumab and Chemotherapy in Advanced NSCLC
NCT06749886Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Progression-Free Survival at 24 months. Started Nov 2024; status: recruiting.
02
Drugs
denosumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06749886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06749886.